Windkracht schreef op 27 februari 2019 13:08:
Een bericht van december 2018. Dit gaat niet over Kiadis maar over een andere partij Kalytera. Zie vooral het deel uit het artikel dat ik hieronder heb gemarkeerd. Potential market huge, and premium pricing.
kalytera.co/news/kalytera-provides-up...The Potential Commercial Opportunity is Large
The commercial opportunity for Kalytera’s CBD product for prevention of acute GVHD is large. Because acute GVHD is a serious and life threatening orphan disease, Kalytera believes that it will be able
to obtain premium pricing for a course of treatment. The incidence of acute GVHD following bone marrow transplantation in the six major markets of the U.S. Germany, the U.K, France, Spain and Japan is above 20,000 patients per year.
Given this addressable market, and the expected premium pricing that Kalytera believes it will obtain, the commercial opportunity for the Company’s CBD product in prevention of acute GVHD is potentially more than USD $1 billion annually